

USSN 09/554,533  
Atty Docket No. 238/086US

## IN THE CLAIMS

Please amend the claims as follows. This listing of claims will replace all prior versions and listings of the claims in the present application.

1-54. (Cancelled)

55. (Currently amended) A peptide compound of the formula:  
His Xaa<sub>2</sub> Xaa<sub>3</sub> Gly Thr Phe Thr Xaa<sub>8</sub> Asp Xaa<sub>10</sub> Ser Lys Gln Xaa<sub>14</sub>  
Glu Glu Glu Ala Val Arg Leu Xaa<sub>22</sub> Xaa<sub>23</sub> Glu Xaa<sub>25</sub> Leu Lys  
Xaa<sub>28</sub> Gly Gly Pro Ser Ser Gly Ala Pro Pro Pro-Z

wherein Xaa<sub>2</sub> is Ser, Gly or Thr,

Xaa<sub>3</sub> is Asp or Glu,

Xaa<sub>8</sub> is Ala, Ser, or Thr,

Xaa<sub>10</sub> is Leu, Ile, Val, pentylglycine or Met,

Xaa<sub>14</sub> is Ala, Leu, Ile, pentylglycine, Val or Met,

Xaa<sub>22</sub> is Phe, Tyr or ~~naphthylalanine~~ naphthylalanine,

Xaa<sub>23</sub> is Ile, Val, Leu, pentylglycine, tert-butylglycine or Met,

Xaa<sub>25</sub> is Ala, Trp, Phe, Tyr or ~~naphthylalanine~~ naphthylalanine,

Xaa<sub>28</sub> is Ala or Asn, and

Z is -OH or -NH<sub>2</sub>; and

pharmaceutically acceptable salts thereof.

56. (Previously presented) The peptide compound of claim 55, wherein Xaa<sub>2</sub> is Ser.

57. (Previously presented) The peptide compound of claim 55, wherein Xaa<sub>2</sub> is Gly.

58. (Previously presented) The peptide compound of claim 55, wherein Xaa<sub>3</sub> is Asp.

59. (Previously presented) The peptide compound of claim 55, wherein Xaa<sub>14</sub> is Leu.

USSN 09/554,533  
Atty Docket No. 238/086US

60. (Previously presented) The peptide compound of claim 55, wherein Xaa<sub>25</sub> is Phe.
61. (Previously presented) The peptide compound of claim 55, wherein Xaa<sub>28</sub> is Ala.
62. (Previously presented) The peptide compound of claim 55, wherein Z is NH<sub>2</sub>.
63. (Withdrawn) A peptide compound of the formula:  
His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Glu Xaa<sub>14</sub> Glu  
Glu Glu Ala Val Arg Leu Phe Ile Glu Xaa<sub>25</sub> Leu Lys Asn-NH<sub>2</sub>;  
wherein Xaa<sub>14</sub> is Ala, Leu, Ile, pentylglycine, Val or Met;  
Xaa<sub>25</sub> is Ala, Trp, Phe, Tyr or ~~naphthylalanine~~ naphthylalanine; and  
wherein any one amino acid other than Xaa<sub>4</sub>, Xaa<sub>7</sub>, Xaa<sub>9</sub>, Xaa<sub>14</sub>, Xaa<sub>18</sub>, Xaa<sub>22</sub> and Xaa<sub>23</sub>  
optionally is Ala; and pharmaceutically acceptable salts thereof.
64. (Withdrawn) The peptide compound of claim 63, wherein Xaa<sub>14</sub> is Leu.
65. (Withdrawn) The peptide compound of claim 63, wherein Xaa<sub>25</sub> is Phe.
66. (Previously presented) A peptide compound of the formula:  
His Xaa<sub>2</sub> Xaa<sub>3</sub> Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu  
Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly  
Pro Ser Ser Gly Ala Pro Pro Pro-Z,  
wherein Xaa<sub>2</sub> is Gly, Ser, Ala or Thr, Xaa<sub>3</sub> is Glu or Asp; and Z is -OH or -NH<sub>2</sub>; and  
pharmaceutically acceptable salts thereof.
67. (Previously presented) The peptide compound of claim 66, wherein Xaa<sub>2</sub> is Ser.
68. (Previously presented) The peptide compound of claim 66, wherein Xaa<sub>3</sub> is Asp.
69. (Previously presented) The peptide compound of claim 66, wherein Z is NH<sub>2</sub>.

USSN 09/554,533  
Atty Docket No. 238/086US

70. (Currently amended) A method for the treatment of diabetes mellitus comprising the administration, to a subject in need thereof, of a therapeutically effective amount of a compound according to claim 55.

71. (Previously presented) The method of claim 70 further comprising the administration of a therapeutically effective amount of an insulin.

72. (Withdrawn) A method for the treatment of diabetes mellitus comprising the administration of a therapeutically effective amount of a compound according to claim 63.

73. (Withdrawn) The method of claim 72 further comprising the administration of a therapeutically effective amount of an insulin.

74. (Currently amended) A method for the treatment of diabetes mellitus comprising the administration, to a subject in need thereof, of a therapeutically effective amount of a compound according to claim 66.

75. (Previously presented) The method of claim 74 further comprising the administration of a therapeutically effective amount of an insulin.